Jefferies Demonstrates Its World Class Capability In High Yield Underwriting

Inverness Medical Innovations

A leader in the global $38 billion in vitro diagnostics (IVD) market, developing capabilities in near-patient diagnosis, monitoring and health management.

PRESS RELEASE EXCERPT:

Published: Aug 6, 2009
Inverness Medical notes price at 98.14 to yield 8.25%; terms

New York, Aug. 6 (LCD) – Inverness Medical Innovations late yesterday completed an offering of senior notes via leads Jefferies, Goldman Sachs, and Wells Fargo, according to sources. The notes priced wide of 8%-area talk, but early gray-market indications suggest a gain on the break. The maker of medical-diagnostic products will use proceeds from its second deal of the year to back its acquisition of Concateno, a London-based supplier of drug-abuse-testing products.

TERMS:

PRESS RELEASE EXCERPT:

Published: Sept 23, 2009
Inverness add-on bonds price at 96.5 to yield 8.6%; terms

New York, Sept. 23 (LCD) – Inverness Medical Innovations today completed a $100 million add-on offering to its 7.875% notes due 2016 via leads Jefferies, Goldman Sachs, and Wells Fargo, according to sources. The maker of medical-diagnostic products will use proceeds to back its acquisition of Free & Clear. Inverness earlier this week detailed plans to acquire Free & Clear for $100 million cash and up to $30 million in future contingent payments based on 2010 revenue.

TERMS: